NeuroSync
PrivateLast Round
Seed
Mar 11, 2019
Total Funding Raised
$4.13M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NeuroSync operates in Healthcare & Life Sciences and is based in Holliston, Massachusetts. Its latest recorded funding round was a Seed round in March 2019.
NeuroSync is a neurotechnology company that provides a cloud-based analytics platform for assessing abnormal eye movements to aid in the diagnosis and treatment of various neurological conditions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Healthcare Analytics, Medical AI, AR/VR Hardware, Sports & Fitness
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroSync Comparables
Compare NeuroSync with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroFlex | 88% | |
| Oculogica | 87% | |
| RightEye | 84% |
For institutional investors. Book with your work email.
NeuroSync Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 11, 2019 | ||||
| Series A Extension | Jan 3, 2018 | ||||
| Seed | Sep 7, 2017 | ||||
| Grant | Jun 13, 2017 | ||||
| Accelerator | Apr 4, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeuroSync Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Quadrant Management | Series A Extension |
| MassChallenge Israel | Grant, Accelerator |
| StartUp Health | Seed |
| Quartus Capital Partners | Growth Equity |
| Oceanic Partners | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Grew 49% QoQ, from 35 to 52 employees.
- Jul 25, 2026
Monthly visitors increased 112% MoM to 5.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asSep 18, 2026
The Entrepreneurs Investment Program recognizes NeuroSync Inc. as 1st Runner-Up among its past winners for pioneering brain-computer interface solutions that revolutionize healthcare and human-computer interaction across Africa.
For institutional investors. Book with your work email.
NeuroSync Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroSync's valuation, stock price, and market status.
Is NeuroSync a public or private company?
NeuroSync is a private company.
What is the current stock price of NeuroSync?
NeuroSync is a private company, so its shares have no public market price. Caplight tracks NeuroSync's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroSync worth (valuation)?
Valuation information for NeuroSync is not publicly available.
Can I buy NeuroSync stock?
NeuroSync shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroSync's last funding round?
NeuroSync's most recent funding round was Seed on March 11, 2019.
Who are the main investors in NeuroSync?
Key investors in NeuroSync include Quadrant Management, StartUp Health, Quartus Capital Partners.
Will NeuroSync IPO soon?
No public IPO plans have been announced for NeuroSync.
How can I track NeuroSync secondary market activity?
Caplight tracks bids, offers, and trades in NeuroSync's shares on secondary markets.